AZ CME Dinner Cover 3HiD.png

CME Dinner Symposium

FREE for 3rd HiD Attendees


Registration Fee to Attend Symposium Only: $100 (includes dinner)


*Please note this session is included in the cost of the 3-day general attendee HiD registration pass.

If you are already registered for HiD, please email to pre-register for this program.

View Dinner Program Brochure

Supported by an Educational Grant from AstraZeneca

Receive 2 AMA PRA Category 1 Credits


Saturday July 13, 2019

7:30 pm – 9:30 pm

Loews Philadelphia Hotel

Philadelphia, PA

For more information, please contact us:  ●  (818) 342-1889


AZ CME Dinner Agenda snip.JPG

Program Description
Diabetes, chronic kidney disease (CKD), and congestive heart failure (CHF)- The CardioRenal Syndrome- share common pathophysiologic origins, including hypertension, inflammation, and increased renin-angiotensin-aldosterone system activity. The risk of CHF & CVD is 2-8 times higher if patients have both diabetes and CKD, and over half of heart failure patients have moderate to severe CKD.
In recent cardiovascular outcomes trials (CVOTs), sodium glucose cotransporter 2 (SGLT2) inhibitors showed a Primary and Secondary prevention of CHF and CKD. These findings have highlighted the pathophysiologic contributions of CKD in the development of CHF and CVD, presenting an important approach to reducing patients’ overall cardiovascular risk.
This satellite symposium will examine and review the optimal approaches to preventing the onset and progression of CKD and CHF in patients with diabetes.


Learning Objectives
Upon completion of this meeting, participants should be able to:
• Describe the prevalence, disease burden, and treatment challenges of CHF and CKD in patients with diabetes
• Describe how the cardiorenal syndrome contributes to the development of CHF- and CVD-related morbidity and mortality in patients with diabetes
• Compare and contrast the effects of different antihyperglycemic agents on heart failure risk in primary vs secondary prevention populations
• Discuss the effects of SGLT2 inhibition on kidney function and CKD risk in patients with diabetes
• Design optimal therapeutic regimens for the prevention of CKD and CHF in patients with diabetes 


Target Audience
This educational initiative is designed for cardiologists, endocrinologists, family physicians, internists, diabetologists, nurse practitioners, physician assistants, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and treatment of diabetes, obesity, cardiovascular disease, and associated conditions, as well as the effect of these conditions on health and society.


Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE
Chair & Program Director: HiD & WCIRDC
Medical Director & Principal Investigator,
Tarzana, California

Mikhail N. Kosiborod MD, FACC, FAHA, 
Chair & Program Director: HiD

Professor of Medicine
Saint Luke's Mid America Heart Institute
University of Missouri-Kansas City

School of Medicine
Kansas City, Missouri

George L. Bakris, MD, MA, Hon. DSc, FASN, FAHA

Professor of Medicine (tenured)
Director, AHA Comprehensive Hypertension Center
The University of Chicago Medicine
Chicago, Illinois

Maria Rosa Costanzo, MD, FAHA,


Medical Director, Heart Failure Research, Advocate Heart Institute
Medical Director, Edward Hospital Center for Advanced Heart Failure
Naperville, Illinois

Javed Butler, MD, MPH, MBA

Professor and Chairman
Department of Medicine
University of Mississippi Medical Center
Oxford, Mississippi


Vice Chief of Medicine
Baylor University Medical Center
Dallas, Texas

Mark E. Cooper, AO, MB BS, PhD,


Head, Department of Diabetes
Central Clinical School
Monash University
Senior Endocrinologist, Alfred Health Clinic
Melbourne, Australia

Matthew R. Weir, MD

Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

AZ CME Dinner end snip.JPG

18372 Clark St.

Suite 212

Tarzana, CA 91356

Phone: 818-342-1889
Fax: 818-342-1538

  • Facebook
  • Twitter